EU-style device regulatory system advocated by Progress & Freedom Foundation.
This article was originally published in The Gray Sheet
Executive SummaryEU-STYLE DEVICE REGULATION RECOMMENDED BY PROGRESS & FREEDOM FOUNDATION, a Washington, D.C.-based think tank with close ties to House Speaker Newt Gingrich (R-Ga.). In a "white paper" on "the future of medical innovation" released June 19, PFF joins the bandwagon of advocates of third-party reviews of medical devices; however, PFF takes the concept a step further by suggesting adoption of the European Union's four-class regulatory system and standards akin to the EU's "essential requirements."
You may also be interested in...
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.